Mateusz Kaczmarek

Mateusz Kaczmarek is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, semiconductors and global market developments. A graduate of the Poznań University of Economics and Business, he previously worked in financial analysis before moving into business journalism. His reporting focuses on technology companies, market trends and the forces shaping global investment markets. Follow Mateusz Kaczmarek on Google News.

Aramark (ARMK) Slides as Q4 2025 Earnings Miss, but 2026 Outlook Stays Strong

Aramark (ARMK) Slides as Q4 2025 Earnings Miss, but 2026 Outlook Stays Strong

Aramark reported its fiscal fourth‑quarter and full‑year 2025 results before the U.S. market opened on Monday, November 17, 2025. The numbers showed strong full‑year growth, record new business wins and a higher dividend — but a softer‑than‑expected Q4 and “lofty” expectations sent the stock lower in today’s session. Business Wire+2Investing.com Canada+2
17 November 2025
··
PowerBank (SUUN) Returns to Profitability: Q1 2026 Earnings, AI Deal and Stock Reaction on 17 November 2025

PowerBank (SUUN) Returns to Profitability: Q1 2026 Earnings, AI Deal and Stock Reaction on 17 November 2025

PowerBank Corporation, the Canadian‑based solar and battery storage developer formerly known as SolarBank, reported a profitable first quarter of fiscal 2026 today and unveiled a fresh milestone in its AI partnership with Intellistake Technologies, sending the thinly traded renewable‑energy stock back into the spotlight. Powerbank Corporation+1
17 November 2025
···
Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics Inc. is back in the spotlight today after investors digested last week’s surprise acquisition agreement with XenoTherapeutics, Inc., a Massachusetts-based non‑profit biotech. The stock is trading sharply higher and unusually active as the market prices in a mostly cash takeover and a complex contingent value right structure that could unlock additional upside over the coming decade. Repare Therapeutics+1
17 November 2025
·
GameStop Stock (GME) on November 17, 2025: Retail Buzz, ‘Trade Anything Day’ Hype and New Short‑Squeeze Speculation

GameStop Stock (GME) on November 17, 2025: Retail Buzz, ‘Trade Anything Day’ Hype and New Short‑Squeeze Speculation

On Monday, November 17, 2025, GameStop is back at the center of the market conversation as its share price hovers just above $20 while retail traders debate new lows, short‑squeeze odds, and the company’s latest viral promotion, “Trade Anything Day.” At the same time, analysts are re‑running their models on GameStop’s valuation after a profitable streak, Bitcoin‑linked treasury moves and a massive convertible note sale earlier this year. markets.businessinsider.com+2Simply Wall St+2
17 November 2025
·
Ford Stock Soars in 2025 as Wall Street Backs EV Reset, Hybrids and an Amazon-Powered Digital Pivot

Ford Stock Soars in 2025 as Wall Street Backs EV Reset, Hybrids and an Amazon-Powered Digital Pivot

Ford Motor Company has quietly become one of 2025’s unlikeliest comeback stories. After years of a sluggish share price, the stock is up roughly one‑third this year, outpacing the broader market, even as its electric‑vehicle unit bleeds billions of dollars. Fresh reports and analyst notes published today, 17 November 2025, show why Wall Street is suddenly “in love” with Ford again — and why the story is more complicated than a simple turnaround. 24/7 Wall St.+1
17 November 2025
···
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race.
17 November 2025
···
1 … 45 46 47 48 49 … 164

Stock Market Today

  • Canadian Natural Resources (TSX:CNQ) Shares Still Appear Undervalued After 308% Rally
    July 25, 2026, 12:59 PM EDT. Shares of Canadian Natural Resources (TSX:CNQ) have climbed 308.4% in the past five years, yet remain undervalued at C$65.48. Trading at a price-to-earnings ratio of 14.0x, lower than the sector average of 24.7x and below the Fair Ratio of 18.3x, the stock trades at a discount to key earnings metrics. With a 59.4% annual return and ongoing carbon capture initiatives, investor sentiment stays upbeat even as broader market caution lingers.